THE VALUE OF VOLUMETRIC MEASUREMENT OF MALIGNANT PLEURAL MESOTHELIOMA (MPM) TO ASSESS THE THERAPY RESPONSE

被引：0
|
作者：
Tutic, M.
Frauenfelder, T. [1 ]
Schramm, A. [2 ]
Goetti, R. P. [3 ]
Weder, W.
Marincek, B. [5 ]
Opitz, I. [4 ]
机构：
[1] Inst Diagnost Radiol, Zurich, Switzerland
[2] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[3] Div Radiol, Zurich, Switzerland
[4] Univ Zurich Hosp, Dept Thorac Surg, CH-8091 Zurich, Switzerland
[5] Inst Radiol, Zurich, Switzerland
来源：
LUNG CANCER | 2009年 / 64卷
关键词：
D O I：
10.1016/S0169-5002(09)70273-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [41] A Retrospective Evaluation of 64 Hospitalised Malignant Pleural Mesothelioma (MPM) Patients
    Ustamujic, Aida
    Cukic, Vesna
    Catovic-Pecanac, Elmedina
    Dizdarevic-Spago, Dina
    Sladic, Irma
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1381 - S1381
  • [42] A phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM).
    Wozniak, Antoinette J.
    Schneider, Bryan J.
    Kalemkerian, Gregory Peter
    Daly, Robert Michael
    Chen, Wei
    Ventimiglia, Jaclyn
    Nagasaka, Misako
    Zauderer, Marjorie Glass
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] The role of VATS decortication in the therapeutic management of malignant pleural mesothelioma (MPM)
    Nakas, A.
    Chamberlain, M. H.
    Ucar, A. E. Martin
    Edwards, J. G.
    Waller, D. A.
    LUNG CANCER, 2007, 57 : S14 - S14
  • [44] Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma (MPM)
    Castagneto, B.
    Santoro, A.
    Ceresoli, G. L.
    Marangolo, M.
    Mencoboni, M.
    Zucali, P.
    Favaretto, A.
    Grossi, F.
    Bearz, A.
    Botta, M.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S18 - S18
  • [45] INCIDENCE, PREVALENCE, AND SURVIVAL OF MALIGNANT PLEURAL MESOTHELIOMA (MPM) IN THE UNITED STATES
    Kim, A.
    Wong, W.
    VALUE IN HEALTH, 2017, 20 (05) : A95 - A95
  • [46] Comparative Value of MR and CT for Tumor Volumetric and Clinical Staging of Malignant Pleural Mesothelioma
    Gill, R.
    Murphy, D.
    Seethamraju, R.
    Bueno, R.
    Richards, W.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1886 - S1886
  • [47] A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM)
    Lee, C. W.
    Anderson, H.
    Martins, H.
    Rao, S. C.
    Sauciuc, D.
    Laurie, S. A.
    Morzycki, W.
    MacNeil, M. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Molecular Characterization of Malignant Pleural Mesothelioma (MPM) by next Generation Sequencing
    Cedres, Susana
    De Castro, Am Martinez
    Pardo, Nuria
    Navarro, Alejandro
    Martinez, Alex
    Amair, Fabiola
    Racca, Fabricio
    Scheenaard, Eulalia
    Recasens, Sergi
    De la Fuente, Iris
    Retter, Andrea
    Vilaro, Marta
    Vivancos, Ana
    Felip, Enriqueta
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1355 - S1356
  • [49] Initial analyses of the IASLC International Database for Malignant Pleural Mesothelioma (MPM)
    Rusch, Valerie W.
    Giroux, Dorothy
    Edwards, John
    Waller, David
    Kennedy, Catherine
    Ruffini, Enrico
    Pass, Harvey
    Rice, David
    Flores, Raja
    de Perrot, Marc
    Crowley, John
    Goldstraw, Peter
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S322 - S323
  • [50] Malignant pleural mesothelioma (MPM): analysis of consecutive 100 patients (pts)
    Abou-Elkasem, F
    Gaafar, R
    Abdelrahman, A
    Abdelbaki, H
    Hassan, N
    PROCEEDINGS OF THE 9TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2004, : 107 - 112
12345